BioMarin price target lowered to $55 from $60 at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on BioMarin (BMRN) to $55 from $60 and keeps a Neutral rating on the shares. The firm says the consensus models for sustained growth of Voxzogo through 2030 and “underestimates disruption ahead.” The drug’s once-daily injection is about to be challenged first by a once-weekly injectable in the U.S., with European approval potentially by Q4, and then by a once-daily oral option in infigratinib starting in early 2027, the analyst tells investors in a research note.